The experimental ZMapp treatment created by Mapp Biopharmaceutical will soon begin human clinical trials in the United States and Liberia, following efforts to boost production capacity.
ZMapp is made using tobacco plants, which can be induced to grow a cocktail of three antibodies. So far, the drug has been used to treat Ebola-infected patients including Brantly, a Spanish priest who succumbed to the disease, a British nurse, and three Liberian health workers. The limited use thus far has yet to reveal however if it is actually effective or not, Fauci says.
"Because the drug was not administered within the context of clinical trials it is not possible to determine whether ZMapp actually benefited those patients in whom it was used."
The U.S. Biomedical Advanced Research and Development Authority have been searching for other biopharmaceutical companies that could make a ZMapp like drug. Since September, it has been working with Regeneron Pharmaceuticals Inc and Roche Holding AG's Genentech unit.